TD Cowen lowered the firm’s price target on InterCure to $5 from $10 and keeps an Outperform rating on the shares. The analyst said they delivered 4Q results that were modestly below our estimates on revenues which grew 33% in the quarter while a clearing of excess wholesale inventory as international operators wind down their revenues was a drag on gross margin.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INCR:
- InterCure Reschedules 2022 Full Year Results Conference Call
- InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results
- InterCure Files Lawsuit Against Cann Pharmaceuticals to Recover Funds Following Failed Merger
- InterCure files suit against Cann Pharmaceuticals following failed merger
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue